Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.5546
-0.0003 (-0.05%)
May 7, 2026, 4:00 PM EDT - Market closed
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,361,750
Market Cap
11.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 1 | 3 |
| Dec 31, 2024 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 43 |
| Lunai Bioworks | 29 |
| BioCardia | 21 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Kiora Pharmaceuticals | 13 |
| Quoin Pharmaceuticals | 5 |
| CDT Equity | 4 |
KAPA News
- 9 days ago - KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 22 days ago - Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation - Business Wire
- 2 months ago - Kairos Pharma to acquire CL-273 from Celyn Therapeutics - TheFly
- 2 months ago - Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics - Business Wire
- 2 months ago - Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn - TheFly
- 2 months ago - Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics - Business Wire
- 3 months ago - Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference - Business Wire
- 4 months ago - Kairos Pharma files $75M mixed securities shelf - TheFly